Money moves in silence. Download 2025 State of Venture Report: a data-driven analysis of active funds, unicorn, and family offices
About usSign in
Status
ACTIVE
Global HQ
Boston, United States
Countries of investment
  • United States
Investment stages
  • Seed
  • Series A
  • Series B
Industries
  • Health Tech
  • Life Sciences
  • Biotechnology
About
RA Capital Management is a Boston-based multi-stage investment firm dedicated to building and supporting life sciences companies, with a strategy rooted in deep scientific research and a commitment to advancing human health.
Min check size
$1M
Max check size
$15M
Fund size
NPS

Investment Thesis

RA Capital Management is a Boston-based healthcare investment firm making both public and private equity investments in biotechnology, healthcare, and planetary health. With approximately $12.6 billion in AUM as of March 2025, RA Capital emphasizes scientific rigor and recently added flexible financing instruments, like royalty and hybrid equity-debt structures to support healthcare companies navigating maturity and capital constraints.
Lead investor
Co Invest
Number of exits
Preferred contact method

Manager's Experience

RA Capital Management, founded in 2002 by biotech veteran Richard Aldrich and biotech-focused managing partner Peter Kolchinsky, now oversees over 12.6 billion dollars in assets with a 130-strong team, demonstrating deep collective experience in healthcare and biotechnology investing.

RA Capital Contacts Information

Primary contact

Secondary contact

Team

Peter Kolchinsky PhD – Managing Partner

Rajeev Shah – Managing Partner

Derek DiRocco PhD – Partner

Portfolio

Abcuro

Adagio Medical

Adcendo

Adcytherix

Adela

Affinia Therapeutics

AgriMetis

Ajax Therapeutics

Aktis Oncology

Alchemab Therapeutics

Alentis Therapeutics

Alpha-9 Oncology

AltruBio

Ambagon Therapeutics

Amplifier Therapeutics

Ansa Biotechnologies

Asher Bio

Avilar Therapeutics

Bambusa Therapeutics

Be Biopharma

BioAge

Bluejay Therapeutics

Bright Peak Therapeutics

Capacity Bio

Capstan Therapeutics

CDR-Life

CellCentric

Cerebral Therapeutics

CiVi Biopharma

Claris Bio

Commons Clinic

Convergent Therapeutics

Coritca

Curevo Vaccine

Delix Therapeutics

Diagonal Therapeutics

Dignify Therapeutics

Electra Therapeutics

Elektrofi

Element Biosciences

Empatica

Enara Bio

Evommune

Fund number
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp